(NASDAQ: SWTX) Springworks Therapeutics's forecast annual revenue growth rate of 342.35% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Springworks Therapeutics's revenue in 2024 is $5,447,000.On average, 5 Wall Street analysts forecast SWTX's revenue for 2024 to be $6,955,590,731, with the lowest SWTX revenue forecast at $4,360,802,540, and the highest SWTX revenue forecast at $9,423,317,975. On average, 4 Wall Street analysts forecast SWTX's revenue for 2025 to be $18,924,481,071, with the lowest SWTX revenue forecast at $14,041,636,604, and the highest SWTX revenue forecast at $27,774,106,326.
In 2026, SWTX is forecast to generate $35,599,348,812 in revenue, with the lowest revenue forecast at $23,370,507,417 and the highest revenue forecast at $44,883,062,077.